Clinical trials: Biopsy
Abnormal Karyotype
The Effectiveness of Blastocentesis Versus Trophectoderm Biopsy
For the purpose of this study, the investigators will perform the removal of trophectoderm (TE) the cells as required for the purpose of pre-implantation genetic screening, in order to perform the genetic analysis.
- Trial name
- NCT02915276
- Testing
- Blastocentisis, Trophectoderm biopsy
- Where
- United Kingdom
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Center for Reproductive an Genetic Health
Healthy Volunteers, Breast Cancer, Metastatic
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System
The purpose of this clinical study is to demonstrate that the Parsortix™ PC1 system enables the capture and harvest of circulating tumor cells (CTCs) from the peripheral blood of patients with metastatic breast cancer (MBC) and…
- Trial name
- HOMING (NCT03427450)
- Testing
- Blood draw
- Where
- 4 sites in United States
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- Angle plc
Lung Diseases
Safety and Effectiveness Study for a Needle Guidance System in Lung Biopsies
This study is designed to provide clinical data regarding safety and clinical effectiveness of the ActiSight Needle Guidance System in assisting radiologically guided percutaneous needle biopsy or aspiration of pulmonary lesions…
- Trial name
- NCT01183182
- Testing
- ActiSight Needle Guidance System
- Where
- 3 sites in Canada
- Volunteers
- 48 people
- Sponsor
- ActiViews Ltd.
Breast Cancer, DCIS
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by…
- Conditions
- Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
- Trial name
- NCT05900986
- Testing
- LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT 0.075 mg/kg
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Integro Theranostics
Healthy Participants
Feasibility Study Aiming at Pre-Analytical Standardization of Whole Blood Processing for Liquid Biopsy Applications
The goal of this feasibility study is to evaluate a new sample preparator called See.d. After blood processing the instrument will produce a set of slides and a tube of plasma.
- Trial name
- NCT05942066
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tethis S.p.A.
Pulmonary Nodule, Solitary, Whole-genome Methylation Sequencing
Benign/Malignant Pulmonary Nodule Classification Based on High-throughput Whole-genome Methylation Sequencing(GM-seq)
Lung cancer is the first cancer in China in terms of morbidity and mortality. The problem of early diagnosis/treatment has always been concerned.
- Trial name
- NCT05415670
- Testing
- Whole-genome Methylation Sequencing(GM-seq)
- Where
- 2 sites in China
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Geneplus-Beijing Co. Ltd.
Lung Cancer
Pilot Study of Biopsy Scanner for Evaluation of Bronchoscopic Small Biopsy Specimens to Determine Adequacy
The aim of the study is to assess the performance of Aquyre Biopsy Scanner technology (the FDA class I medical device) at determining if tissue from the lymph nodes and lung nodules, taken during a bronchoscopy procedure, is…
- Trial name
- NCT05393154
- Testing
- Biopsy Adequacy Evaluation by Aquyre Biopsy Scanner
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Aquyre Bioscience, Inc
Lung Cancer
superDimension™ Navigation System Version 7.2 With Fluoroscopic Navigation Technology
The purpose of this investigation is to confirm the clinical accuracy of the superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology.
- Trial name
- NCT03585959
- Testing
- superDimension™ Navigation System Version 7.2
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Medtronic - MITG
Lung Cancer
InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology
The objective of the study is to evaluate the feasibility of the BioSpy System sensor to differentiate tissues that are encountered during bronchoscopic biopsy of endobronchial tumors and peripheral lung nodules and masses.
- Trial name
- INSPECT (NCT06380361)
- Testing
- BioSpy System
- Where
- 2 sites in Australia, France
- Volunteers
- 30 people
- Sponsor
- Sensome
Chronic Kidney Diseases, Type 1 Diabetes Mellitus
Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
The purpose of this study is to assess the safety, efficacy, and durability of up to two Renal Autologous Cell Therapy (REACT) / rilparencel injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys…
- Conditions
- Chronic Kidney Diseases, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Trial name
- NCT05018416
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Prokidney
Myelogenous Leukemia, Chronic
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg twice daily, were compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+)…
- Trial name
- ENESTnd (NCT00471497)
- Testing
- nilotinib, imatinib
- Where
- 213 sites in United States, Argentina and 33 more
- Volunteers
- 846 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Prospective Study of oncRNA Stratification of Cancer by Size and Stage
Cancer strikes about one in three women and one in two men in the U.S. and more than 600,000 die from it each year. The best chance to reduce these numbers and save lives is through early detection and intervention.
- Trial name
- NCT05833360
- Testing
- Exai oncRNA blood test
- Where
- 2 sites in United States
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Exai Bio Inc.
Liver Transplantation
Non-Invasive Rapid Assessment of Patients With Liver Transplants Using Magnetic Resonance Imaging With LiverMultiScan
This will be a prospective, multi-centre, biomarker trial comparing the accuracy of a new test (LiverMultiScan) against an existing test (liver biopsy) in the assessment of liver transplant recipients, designed in accordance with…
- Trial name
- RADIcAL2 (NCT03165201)
- Testing
- LiverMultiScan
- Where
- 3 sites in Netherlands, Portugal and 1 more
- Volunteers
- 131 people
- Sponsor
- Perspectum
Low Bone Mass, Low Bone Mineral Density
A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
To characterize the effects of discontinuation of denosumab therapy on variables of bone histology in postmenopausal women with low bone mass or osteoporosis.
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Osteoporosis, Postmenopausal Osteoporosis
- Trial name
- NCT00887965
- Testing
- Previous denosumab
- Volunteers
- 15 people
- Sponsor
- Amgen
Renal Transplant
24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients
The objective of the study is to compare the cardiovascular profile of an everolimus and mycophenolic acid immunosuppressive regimen with a calcineurin inhibitor and mycophenolic acid regimen in maintenance renal transplant…
- Trial name
- EVITA (NCT01169701)
- Testing
- Everolimus, Tacrolimus, Mycophenolic acid (MPA)
- Where
- 9 sites in Spain
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers
Biopsy Study for Sculptra (Poly-L-Lactic Acid)
The primary objective of this study involves research to evaluate new collagen (the elastic fibers that provide skin with its strength and resilience) formation in the skin following injections of Sculptra (Poly-L-Lactic Acid or…
- Trial name
- NCT00869687
- Testing
- Poly-L-Lactic Acid Injection
- Where
- Canada
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Lung Cancer
An Observational Study on the Assessment of Lung Cancer Using Liquid Biopsy for Collecting miRNA Expression Profile and DNA Methylation Biomarkers.
The purpose of this study is to observe whether miRNA and DNA methylation collected through liquid biopsy can serve as a biomarker for evaluating lung cancer.
- Trial name
- NCT07182214
- Testing
- Collect blood sample
- Where
- Taiwan
- Volunteers
- 1,340 people
- Sponsor
- Pharus Taiwan, Inc.
Pancreatic Cancer
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.
- Trial name
- NCT01632306
- Testing
- LY2090314, FOLFOX, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Eli Lilly and Company
Congenital Bleeding Disorder, Healthy
Dose Response to Recombinant Factor VIIa When Administered for Bleed
This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed.
- Trial name
- NCT00104455
- Testing
- activated recombinant human factor VII
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Primary Liver Cancer, Hepatocellular Carcinoma
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
To evaluate the predictive value of ctDNA in response, relapse for liver cancer patients treated with immune checkpoint inhibitors
- Conditions
- Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Combined Hepatocellular-cholangiocarcinoma
- Trial name
- NCT05292443
- Testing
- Observation
- Where
- 5 sites in China
- Sponsor
- Geneplus-Beijing Co. Ltd.